Find partners
After Market

After Market

Hosted by Proactive Australia

BusinessInvestingNewsInterviews guests

Episodes

20

Latest episode

Jun 2025

Language

EN

About the show

Welcome to After Market, the podcast from Proactive Australia with its finger firmly on the investor pulse. Each month we take a closer look at the issues shaping and shifting the markets - from cost of living to climate, geopolitics to geology, macroeconomics to medtech and big data to battery metals. Please note that the views of our interviewees are not the views of Proactive Investors. Seek independent investment advice before making any financial decisions and remember that nothing you hear on this pod constitutes investment advice.

Listen to episodes

20 recent
June 4, 202511 min

ASX companies turn to OTC Markets for dual listing

In this episode, OTC Markets Group executive vice president Jason Paltrowitz joins Proactive to discuss how international companies—especially those listed on the Australian Securities Exchange (ASX)—can efficiently expand their reach to United States investors through secondary trading on OTC Markets. Paltrowitz explains the challenges U.S. investors face when trying to access equities listed on overseas exchanges such as the ASX, London Stock Exchange, or Euronext Paris. He outlines how OTC Markets bridges this gap by allowing these companies to make their shares available in U.S. dollars during U.S. trading hours, through regulated trading platforms. The episode also explores OTC Markets’ three-tiered structure, with a focus on OTCQX—the “best market”—and OTCQB, the “venture market,” tailored for growth-stage companies. Over 80 ASX-listed companies are already leveraging these platforms. Paltrowitz introduces the “List Local, Trade Global” strategy, enabling firms to maintain their primary listings at home while gaining exposure to U.S. liquidity—without the added burden of full U.S. regulatory compliance such as SEC filing or Sarbanes-Oxley. The conversation concludes with a look at rising U.S. investor interest in international equities—Asian and European trading volumes have surged—and previews upcoming innovations like overnight trading and the OTCID platform aimed at enhancing market access and transparency.

March 28, 202525 min

Safer chemotherapy? Race Oncology’s new drug heads to trials

Race Oncology Ltd is advancing the development of a reformulated chemotherapy drug aimed at reducing severe side effects, particularly cardiac-related risks, while preserving or improving efficacy. In this episode of After Market with Jonathan Jackson, CEO and managing director Daniel Tillett highlighted the drug’s potential to work alongside anthracyclines, a common class of chemotherapy agents, to enhance patient safety and treatment outcomes. The company is preparing for clinical trials to evaluate the drug’s performance in human subjects.

May 28, 202428 min

The state of drug development in Australia: a case study

Amplia Therapeutics Ltd CEO and managing director Dr Chris Burns has had a long career in drug development, including discovering only the second Australian drug to receive US FDA approval. He has plenty of advice to share for Australian-based researchers and domestically developed biotech assets. Proactive's Susanna Nelson chats to him about the current state of clinical research and commercial drug development in Australia.

March 14, 202418 min

Australian Vanadium reinforces potential for long-lasting, high-grade vanadium and battery metal project

Australian Vanadium Ltd (ASX:AVL) CEO Graham Arvidson sits down with Proactive’s Jonathan Jackson to discuss progress in the company's metallurgical testing following a recent merger with Technology Metals Australia Ltd (TMT). AVL plans to capitalise on the battery metal boom with its vanadium and high-grade iron project, leveraging its subsidiary VSUN to build out the Vanadium Flow Battery market and other future tech applications.

February 13, 202415 min

Carbon capture and storage: An essential part of the circular economy

How can resource companies mitigate their carbon emissions in innovative ways? Proactive’s Phoebe Shields talks to CSIRO’s Dr Dia Milani, who leads the organisation’s CO2 utilisation team within the Sustainable Carbon Technologies group, about the urgency of including carbon capture and storage methods in the mix of tools to combat climate change – and the opportunities that abound for companies to apply the technology in Australia.

January 5, 202418 min

Artemis Resources is chasing gold, copper and lithium in the Pilbara

Artemis Resources Ltd executive director George Ventouras talks to Proactive’s Susanna Nelson about the company’s projects, mostly in the West Pilbara, where it is exploring for gold, copper and lithium. George also weighs in on ‘the white gold boom’, the importance of a diverse and sustainable mining industry to the Australian economy and the future of mining in this country.

December 4, 202321 min

How does Australia get the best out of its relationship with China?

China is our biggest trading partner. In this introduction to the topic, mining publisher and China entrepreneur Yolanda Torrisi tells Proactive about the Australian industries that are most exposed to the trading giant, whether diplomatic relations are starting to defrost, and how we can leverage the relationship to our best advantage at a time of uncertainty for global markets and supply chains.

November 17, 20236 min

Provaris an early mover on green hydrogen supply chain in Europe

Energy security is critical in these days of geopolitical unrest. Provaris Energy Ltd has seen the writing on the wall and has forged ahead with its business model of simple and efficient hydrogen production and transportation. MD and CEO Martin Carolan tells Proactive's Susanna Nelson the company is currently in the design phase of a prototype tank for compressed hydrogen, with construction and testing planned in Norway for the first quarter of 2024. A range of government and independent stakeholders are interested, too.

November 7, 202323 min

Moving clinical trials out of the hospital and into general practice

Clinical trials are, by necessity, subject to rigorous guidelines to protect human health. Proactive’s Phoebe Shields talks to Evrima founder and CEO Charlotte Bradshaw about her company’s data-driven patient matching system, which verifies and matches participants’ electronic medical records to trial protocols. This breaks down barriers to trial recruitment such as awareness, hospital-centricity, distribution of patients, commitment to participation and suitability to take part.

November 3, 20238 min

Imugene forges ahead with VAXINIA trial targeting solid tumours

Clinical-stage immuno-oncology biotech Imugene has been making significant strides in the development of therapies targeting a range of cancers. In this episode of After Market, MD and CEO Leslie Chong tells Susanna Nelson about the company's Phase 1 metastatic advanced solid tumours, or MAST, trial, which has been designed to evaluate the safety and efficacy of the cancer-killing virus CF33-hNIS (VAXINIA).

Is this your show?

Claim this listing to keep it up to date, reach guests who want to pitch you, and manage bookings with Guestify.

Claim this listing

More Business podcasts